Targeted attack on lingering cancer cells after transplant
NCT ID NCT04876248
Summary
This study tests whether adding a targeted drug called belantamab mafodotin to standard lenalidomide treatment can eliminate tiny amounts of remaining cancer cells in multiple myeloma patients who have had a stem cell transplant. The goal is to help patients achieve and maintain a deeper remission. Researchers will measure whether this combination can clear these residual cancer cells and keep the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.